Clinical trial NCT05731700: CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
Official title: Everolimus-Coated Percutaneous Transluminal Coronary Angioplasty Catheter First in Human Clinical Investigation: A Clinical Evaluation in the Treatment of Subjects With In-Stent Restenosis of Previously-treated Coronary Artery Lesions
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: In-stent Restenosis
Keywords: TP1125
Coronary
CVT
CVT-ISR
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2023-02-16
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

Detailed description: The CVT-ISR Trial is a prospective, multi-center, open, single arm study enrolling subjects with visually estimated nominal vessel diameter ≥2.0 mm and ≤3.5mm and lesion length ≤24 mm receiving up to two (2) CVT Everolimus CVT EVE-PTCA Catheters.

An angiographic follow up, in combination with either Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), follow-up, will be carried out in a subset of 25 patients at 180 days following the index procedure.

Eligibility criteria: Inclusion Criteria:

1. Subject must be at least 18 years of age.
2. Subject or his/her legally authorized representative provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site.
3. Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms, IVUS/OCT and examinations.

Angiographic Inclusion Criteria

1. Target lesion must be located within a stent (bare metal or drug eluting) placed in a native epicardial coronary vessel with visually estimated nominal vessel diameter of ≥2.0mm and ≤3.5mm.
2. Target lesion must measure ≤24 mm in length by visual estimation.
3. The target lesion must be with a visually estimated stenosis of ≥50% and \< 100% with a TIMI flow of ≥1.
4. Non-clinical investigation, percutaneous intervention for lesions in a non-target vessel is allowed if done ≥90 days prior to or planned to be done 6 months after the index procedure.
5. Non-clinical investigation, percutaneous intervention for lesions in the target vessel is allowed if planned to be done 6 months after the index procedure.

Exclusion Criteria:

1. Subject with known diagnosis of acute myocardial infarction (AMI) within 30 days preceding the index procedure and CK-MB or troponin have not returned within normal limits at the time of procedure.
2. The subject is currently experiencing clinical symptoms consistent with AMI.
3. Subject has current unstable arrhythmia.
4. Subject has a known left ventricular ejection fraction (LVEF) \<25%.
5. Subject has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine and structurally related compounds, everolimus, or contrast sensitivity that cannot be adequately pre-medicated.
6. Subject has known renal insufficiency (e.g., serum creatinine \> 2.5 mg/dL, (i.e. 221 µmol/L) within 7 days prior to index procedure or creatinine clearance \<30mL/min or subject is on dialysis.
7. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
8. Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months.
9. Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
10. Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
11. Subject is not, in the opinion of the investigator, an acceptable candidate to participate in the study.
12. In-stent lesions for stent are located within an arterial or saphenous vein graft or stent used to treat a previous ISR.
13. The target vessel contains visible thrombus.
14. Pregnant or lactating females.

Primary outcomes:
measure: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate
timeFrame: 6 months post-index procedure
measure: The Primary Effectiveness Endpoint for the CVT-ISR Study: In-stent Late Lumen Loss (LLL)
timeFrame: 180 days post-procedure
Secondary outcomes:
measure: Composite Rate of Target Lesion Failure (TLF)
timeFrame: 30 days post-procedure and 12 months
measure: Composite Rate of Target Vessel Failure (TVF)
timeFrame: 30 days post-procedure, 180 days and 12 months
measure: Clinically Driven Target Lesion Revascularization (TLR)
timeFrame: 12 months
measure: Clinically-driven Target Vessel Revascularization (TVR)
timeFrame: 180 days and 12 months
measure: Rate of Vascular Access Site Complications
timeFrame: 12 months
measure: Lesion Success:
timeFrame: 12 months
measure: Technical Success
timeFrame: 12 months
measure: Clinical Success (Per Subject)
timeFrame: 12 months
measure: Procedural Success
timeFrame: 12 months
Other outcomes:
Locations:
city: Grenoble
country: France
facility: Groupe Hospitalier Mutualiste de Grenoble
city: Nantes
country: France
facility: L'Hôpital Privé du Confluent
city: Toulouse
country: France
facility: Clinique Pasteur
city: Tbilisi
country: Georgia
facility: Tbilisi Heart and Vascular Clinic
city: Tbilisi
country: Georgia
facility: Georgian Israeli Research Medical Centre Helsicore
city: Vilnius
country: Lithuania
facility: Vilniaus universiteto ligoninė Santaros klinikos
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
city: Madrid
country: Spain
facility: Hospital Universitario de La Princesa
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
Study officials:
References: